Law and legal

United States Apellis Tender

📄 Tender ID: 504468159 📅 Published: 03 Jun 2024

📋 Tender Overview

On May 14, 2024, Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), announced that it has entered into a non-dilutive, senior secured credit facility with Sixth Street, a leading global investment firm, of up to $475 million, with approximately $375 million funded at close. Apellis can draw down an additional $100 million under the facility at the company’s option prior to September 2025, subject to the satisfaction of certain conditions.

Additionally, the Sixth Street agreement also permits Apellis to access $100 million through a separate third-party working capital facility. Apellis used the majority of the net proceeds to buy out the existing SFJ Pharmaceuticals development liability for approximately $326 million. This buy out eliminates $366 million in payments owed to SFJ through 2027, including approximately $200 million through 2025. Net proceeds to Apellis at closing will be approximately $32 million following the buy out of the SFJ Pharmaceuticals development liability, and fees and expenses associated with the transaction.

🔍 Key Information

📄
Tender Reference No.
504468159
📅
Publication Date
03 Jun 2024
🌐
Sector
Law and legal
📝
Notice Type
News
📍
Location
United states

📁 Documents & Downloads

No documents found

🏷️ CPV

No CPV found

Need help with this bid?

Our bid experts can help you find, evaluate & win more tenders.

🎧 Talk to Bid Expert
🕒 Submission deadline
0
days remaining · 03 Jun 2024
🔔 Set Alert

🧭 Quick Facts

Authority N/A
Country United states
State / UT N/A
Tender Type Procurement News
Currency N/A
Similar Tenders
Loading similar tenders…